The median PRS was higher in LA group, followed by LB, TN and HER2-enriched (Median survival: 75, 37, 34 and 19 months for LA, LB, TN and HER2-enriched respectively) but these differences did not reach statistical significance.
← all excerpts
Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence
1
—
—